Introduction
A number of cases of end organ resistance to the action of thyroid hormone has been reported over the past few years (Bode, Danon and Weintrub, 1973; Elewant, Mussche and Vermenten, 1976) . In some cases the defect appears to lie only at pituitary level, with inappropriately elevated levels of thyroid stimulating hormone for thyroid hormone levels at or above the upper end of the normal range, and clinical features of thyrotoxicosis (Gershengorn and Weintrub, 1975) . Other cases have been described with a more generalized end organ resistance, with clinical features including deaf mutism, goitre and stippled bony epiphyses (Refetoff, De Wind and De Groot, 1967) . Recent evidence suggests that in some cases there is reduced affinity of nuclear receptors for T3 (Daubresse et al., 1980) . These previously reported cases with normal thyroid gland function, however, responded to chronically elevated thyroid-stimulating hormone (TSH) concentrations with goitre formation. Reports have also been made of an elevation in the threshold for TSH suppression by thyroid hormone in congenital hypothyroidism, which may be regarded as a partial end organ resistance phenomenon (Schultz, Glassman and MacGillivray, 1980; Sato et al., 1977 In an effort to gauge the tissue response to circulating thyroid hormone, left ventricular contractility was assessed by measuring systolic time intervals, using the method described by Parisi et al. (1974 (Schultz et al., 1980; Sato et al., 1977) . Schultz et al. (1980) (Sato et al., 1977) .
In the present case, however, the abnormality in TSH suppressibility was only detected after 8 years of thyroxine therapy, in doses which were clinically and biochemically (in terms of PBI and total T4) adequate. This does not accord with the hypothesis of Sato et al. stated above, and suggests that, in some children at least, the elevated threshold for TSH suppression may be a more prolonged, or even a permanent feature.
In current management of children with hypothyroidism, attainment of T3 and T4 levels in the 'normal' range, and the suppression of an elevated TSH level are taken as guides to the adequacy of therapy (Rezvani and Di George, 1977) . The authors would, however, extend the caveat expressed 
